Example: stock market

조터나 흡입용캡슐 - Novartis Korea

1 / 11 ( / ) - 110/50mcg Xoterna (indacaterol maleate/glycopyrronium bromide) 1 : ( ) ( 110mcg) ( ) ( 50mcg) : ( ) ( ) : 1 1 , 1 ( ) . , . 1 1 .. , , . (5. 6) ).. (5. 7) ). 2 / 11 18 . 75 . 1. 1) 1 1 1 ( ).

페이지 2 / 11 이 약은 18세 미만의 소아 환자에게 투여하지 않는다. 고령자 75세 이상 고령자에게 투여 시 용량 조절은 필요하지 않다.

Tags:

  Novartis

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of 조터나 흡입용캡슐 - Novartis Korea

1 1 / 11 ( / ) - 110/50mcg Xoterna (indacaterol maleate/glycopyrronium bromide) 1 : ( ) ( 110mcg) ( ) ( 50mcg) : ( ) ( ) : 1 1 , 1 ( ) . , . 1 1 .. , , . (5. 6) ).. (5. 7) ). 2 / 11 18 . 75 . 1. 1) 1 1 1 ( ).

2 2) (paradoxic bronchospasm) .. 3) 2- (LABA:Long acting beta2-adrenergic agonists) , , . , . 4) , .. , . 2. 1) 2) (1. 3) ) 3) , (galactose intolerance), Lapp (Lapp lactase deficiency) - (glucose-galactose malabsorption) . 3. 1) ( , , ) (5. 3) ) 2) 3) 4) 2- 5) 6) 3 / 11 7) 8) 9) (5.

3 6) ) 10) 4 ( ) . 4. 1) 15 .. , .. ( ) . 2) ~ 6 , 12 2 3 6 MedDRA system .. : ( 1/10), ( 1/100, < 1/10), ( 1/1000, < 1/100), ( 1/10,000, < 1/1,000), (<1/10,000). / 110/50 g/1 1 , n=699 N(%) n=345 N(%) - 81 ( ) 56 ( ) - 37 ( ) 24 ( ) - 13 ( ) 3 ( ) - 11 ( ) 2 ( ) - 8 ( ) 3 ( ) - 1 ( ) (0) - 3 ( ) 5 ( ) 4 / 11 - 4 ( ) 2 ( ) - 12 ( ) 3 ( ) - 21 ( ) 5 ( ) - 1 ( ) (0) - 1 ( ) (0) - 3 ( ) 1 ( ) - 1 ( ) (0) - 1 ( ) 3 ( ) - 6 ( ) 4 ( ) , - 40 ( ) 11 ( ) - 23 ( ) 9 ( ) - 3 ( ) (0) - 15 ( ) 4 ( ) - 8 ( ) 2 ( ) - 4 ( ) 1 ( ) - / 5 ( ) 2 ( ) - 7 ( ) 1 ( ) - 5 ( ) (0) - 5 ( ) 1 ( ) 5 / 11 - 4 ( )

4 (0) - * 15 ( ) 5 ( ) - 11 ( ) 2 ( ) - 2 ( ) 3 ( ) - 5 ( ) 1 ( ) * , , , 2 . 3) ( ) : - 5. 1) . 2) : . , ( , , ) . 3) 2- , , / , . - T (flattening), QT , ST (segment) , . , , , ( ), QT QTcF ( 450ms).

5 4) : 2- 6 / 11 .. , (6. ). 5) 2- . 6) , . , . : , . : . AUClast , . (eGFR < 30mL/ ) .. 7) , .. : .. : .. 6. 1) (steady-state).

6 2) , . 3) ( ), ( , ), , , QTc , . MAO 2- . , , 2- . 7 / 11 : ( ) . (methylxanthine) , (non-potassium sparing diuretics) 2- (5. 4) ). - ( ) : 2- . - , . CYP3A4 P- (P-glycoprotein, P-gp) ( , , ) : AUC ~ 2 , Cmax , AUC ~ , Cmax . AUC 2 , Cmax , AUC ~ , Cmax.

7 CYP3A4 P- (P-glycoprotein, P-gp) . 600 1 , .. in vitro . 4) . (AUC) 22% (CLr) 23% . , . in vitro / .. 7. 1) , .. 8 / 11 , .. 2) 2- . 3).

8 ( ) .. 4) (12. ). 8. 18 . 9. 1) 1 4 , , QTc , . 2) 2 600/100 , , QTc , . 300/100 600/100 14 . (600/100 49 , 300/100 51 ) . 4 . 3) 3000 , , QTc . 2 , , , , , , , , , , .. 4) . 9 / 11 28 1 1 , 1 100 200 . ( 5%).

9 120 , (1 1 50 ) 50 , 6 , . 10. 1) ( ) . 2) . 3) .. 4) ( ) , . 5) ( ) .. : . : .. : . : .. : . : , .. : .. : - , .. , . , .. 10 / 11.

10 , . : , 5~10 .. , , , , .. , .. , .. : . 11. 1) 25 C . 2) . 3) . 12. 1) . , (additive response) . 2) 2- ( , , ) .. , 14 F1 .. 11 / 11 . 2 , 6.


Related search queries